Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vistagen Therap. Com (VTGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,038
  • Shares Outstanding, K 22,900
  • Annual Sales, $ 1,250 K
  • Annual Income, $ -10,260 K
  • 36-Month Beta -0.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.89
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.05
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/12/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.81 +2.48%
on 04/23/18
1.20 -30.83%
on 04/18/18
-0.34 (-29.05%)
since 03/23/18
3-Month
0.81 +2.48%
on 04/23/18
1.66 -49.99%
on 01/26/18
-0.84 (-50.29%)
since 01/25/18
52-Week
0.69 +20.30%
on 11/29/17
2.65 -68.68%
on 12/07/17
-1.14 (-57.86%)
since 04/25/17

Most Recent Stories

More News
This Morning's Technical Outlook on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM Oncology

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on VCEL, VKTX, VTGN, and ZIOP which can be accessed for free by signing up to www.wallstequities.com/registration....

VKTX : 3.95 (-4.13%)
ZIOP : 4.28 (+0.23%)
VCEL : 11.90 (-1.24%)
VTGN : 0.84 (-4.55%)
VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101

SOUTH SAN FRANCISCO, CA--(Marketwired - April 10, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and...

VTGN : 0.84 (-4.55%)
VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder

SOUTH SAN FRANCISCO, CA--(Marketwired - April 05, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and...

VTGN : 0.84 (-4.55%)
VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101

SOUTH SAN FRANCISCO, CA--(Marketwired - March 19, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other...

VTGN : 0.84 (-4.55%)
Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM Oncology

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on VCEL, VKTX, VTGN, and ZIOP which can be accessed for free by signing up to www.wallstequities.com/registration....

VKTX : 3.95 (-4.13%)
ZIOP : 4.28 (+0.23%)
VCEL : 11.90 (-1.24%)
VTGN : 0.84 (-4.55%)
VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101

SAN FRANCISCO, CA--(Marketwired - March 07, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central...

VTGN : 0.84 (-4.55%)
VistaGen Therapeutics to Present at Oppenheimer's 28th Annual Healthcare Conference on March 21, 2018

SOUTH SAN FRANCISCO, CA--(Marketwired - March 05, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other...

VTGN : 0.84 (-4.55%)
VistaGen Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference on March 14, 2018

SOUTH SAN FRANCISCO, CA--(Marketwired - February 27, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and...

VTGN : 0.84 (-4.55%)
Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM Oncology

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on VCEL, VKTX, VTGN, and ZIOP which can be accessed for free by signing up to www.wallstequities.com/registration....

VKTX : 3.95 (-4.13%)
ZIOP : 4.28 (+0.23%)
VCEL : 11.90 (-1.24%)
VTGN : 0.84 (-4.55%)
VistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets' Investor Conference

SOUTH SAN FRANCISCO, CA--(Marketwired - January 22, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 0.84 (-4.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

2nd Resistance Point 0.94
1st Resistance Point 0.91
Last Price 0.84
1st Support Level 0.85
2nd Support Level 0.82

See More

52-Week High 2.65
Fibonacci 61.8% 1.90
Fibonacci 50% 1.67
Fibonacci 38.2% 1.44
Last Price 0.84
52-Week Low 0.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar